Replies to post #787337 on NorthWest Biotherapeutics Inc (NWBO)

[danielboog2]

GEEZ....Twisted Logic.......you're a moderator.....delete your post?????????

[SkyLimit2022]

e❌,

Thanks for reposting your x-ceptional insights 😶

Fact ✅️:
It’s not “stalled.” It has progressed and advanced into a new era of combos. DC combos with TLR & PD1 technologies are relatively new and combo studies have only reached P2. (Additionally, the commpassionate use Specials Program is ongoing today and continues to produce more and more safety & efficacy data beyond the data collected from the landmark P3 which does not include any data about PD1 or TLR agents)…

Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO and Dr. Kalinski recently cited MTA agreements with Merck.

Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.



clinicaltraials.gov NCT04201873

⭐️Combo is King!⭐️




⭐️ AACR Advances in Ovarian Cancer Research

⭐️ NWBO to Acquire Advent BioServices

⭐️ Recent Conference

⭐️ DCVax-L Combo PII UCLA

⭐️ DC Combo PII Roswell Park

⭐️ 10-Q Quarterly Report

⭐️ 10-K Annual Report

⭐️ NICE UK 🇬🇧 DCVax-L

⭐️ ASM June 29, 2024

⭐️ Manufacturing Technology

⭐️ NWBO Acquires Flaskworks

⭐️ Roswell Park IP Portfolio

⭐️ TLR3 agonist Ampligen (rintatolimod)

⭐️ Next Generation Dendritic Cell Treatments




















AI Fact-Checking

[danielboog2]

EXWANNABE:

But LP did not want to take her lumps., And you supported this. So the delay in -L is all on you and your palls.

So take your crap and shove it.

PALS....get a grip. You're losing. And will lose until the very end.....

My Quote:

If you stay, then it's for one reason....TO CAUSE DAMAGE TO NWBO and those SUFFERING FROM CANCER.....SICKENING

Pure simple logic and absolutely the REALITY

[CherryTree1]

Stalled HA more like Turbo Charged . . . They've been a little busy the past decade, even just looking back 5 years.
August 2020 NWBO acquired Flaskworks, LLC
October 2020: NWBO announced the data lock for their Phase III trial of DCVax-L for Glioblastoma
December 2021: UK Manufacturing License
March 2022: Positive Top-Line Results
August 2022: Regulatory Approval for Pediatric Plan
December 2023: Submission of MAA
February 2024: Moving towards the production of GMP-compliant units?
February 2024: Market manipulation lawsuit: Ruling that favored NWBO's pleading
March 2024: Board Appointment
May 2024: Nature article about results of DCvax-L in combo with poly-iclc: Enhanced Immune Response, Improved Survival, Safety and Biomarker Identification
June 2024: Exclusive In-License of Dendritic Cell Technology
NWBO secured an exclusive license for a portfolio of advanced dendritic cell technologies from the Roswell Park Comprehensive Cancer Center.
August 2024: Primary completion date for SPORE 1 combo trial at UCLA with DCvax-L and Keytruda
January 2025: Market manipulation lawsuit: A magistrate judge issued a report in January 2025 concluding that NWBO had sufficiently pled its market manipulation claims in an ongoing lawsuit.
Throughout 2025: Advancements in Flaskworks technology: NWBO continued developing its automated Flaskworks technology for manufacturing cell therapies to enhance scalability and reduce costs.
2025: NWBO advances its DCVax-Direct program for inoperable solid tumors, with plans for Phase 2 trials in 2025.
June 2025: Dr. Marnix Bosch, its Chief Technical Officer to present on next-generation dendritic cell treatments at the Frontiers in Cancer Immunotherapy Conference.
August 2025: NWBO announces acquisition of Advent to enhance its manufacturing capabilities. The acquisition includes Advent's fixed assets, cryostorage equipment, and intellectual property.